Biotech

All Articles

Amgen records first phase 3 gain for $400M dermatitis drug

.Amgen has actually shared (PDF) the first phase 3 information on its own $400 thousand chronic ecze...

Biogen, UCB record period 3 lupus win after failing earlier test

.Biogen and also UCB's bet one's bottom dollar developing right into stage 3 on the back of an unsuc...

Aptadir hopes brand-new RNA inhibitors can easily turn around challenging cancers

.Italian biotech Aptadir Rehabs has actually introduced along with the pledge that its pipeline of p...

Wave surfs DMD excellence to regulators' doors, sending stock up

.Surge Lifestyle Sciences has actually met its own objective in a Duchenne muscular dystrophy (DMD) ...

Sanofi tweezes brand new CSO from in-stealth biotech

.After a few years in biotech, Mike Quigley, Ph.D., is returning to the pharma crease, occupying the...

Achilles drops tissue treatment course, prepares for discharges after overlooking 'commercial practicality' targets

.Achilles Therapies has wrecked its method. The British biotech is stopping work on its own clinical...

Aligos advertises period 2 MASH win, slashing liver fat approximately 46%

.Aligos Rehabs is heralding a midstage win in metabolic-dysfunction linked steatohepatitis (MASH) af...

Basilea credit ratings $268M BARDA financing for antifungals, anti-biotics

.Basilea Pharmaceutica's work developing new antifungals has actually obtained a considerable increa...

Capricor offers Europe civil rights to late-stage DMD treatment for $35M

.Possessing currently scooped up the U.S. civil liberties to Capricor Therapies' late-stage Duchenne...

FDA junks adcomm for Applied's uncommon health condition drug

.After dismissing the decision date for Applied Therapeutics' metabolic disorder drug govorestat, th...